Use of Multispot HIV-1/HIV-2 Rapid Test to confirm HIV-1/HIV-2 Plus O Enzyme Immunoassay results, shorten reporting time for HIV testing and identify cryptic HIV-2 infection

J Dragavon, C Gallardo, E Espinosa, JP Ortega, S Harb, J Steckler and RW Coombs

Departments of Laboratory Medicine & Medicine, University of Washington, Seattle, WA
Objective

- To test an alternative HIV testing strategy that provides timely and accurate results for clinicians
Hypothesis

- A combination of routine HIV-1/2 EIA and simple, rapid antibody testing would improve reporting turn-around-time in an academic clinical diagnostic laboratory setting
  - Evaluate an algorithm similar to the APHL/CDC HIV testing Laboratory Algorithm 3: “Dual HIV-1/HIV-2 Immunoassay,” using routine EIA and a simple, rapid antibody test
  - Test the accuracy of reporting “presumptive HIV infection”
Rationale

- Traditional laboratory diagnostic testing
  - Screening with EIA (or CIA) and reactive results are confirmed by supplemental testing before releasing test results (WB or IFA): MMWR 1989: 38(S-7):1-7

- Point-of-Care
  - Reporting of a single test result as “preliminary positive” for HIV-1 and/or HIV-2 antibodies is accepted as standard of care: MMWR 2001; 52(RR19): 1-58 and ibid 2004; 53(10): 221-222

- Marriage of a 3rd generation EIA (or CIA) and simple/rapid antibody test is the logical next step
**Laboratory Algorithm 3: Dual HIV-1/HIV-2 Immunoassay**

*A2* must ust be a different EIA, CIA or rapid test from *A1*: i.e., “orthogonality”

**If a seronegative-window period infection is suspected (based on risk assessment or discordant testing) refer to Acute HIV Infection Testing Laboratory Algorithm 4

†Adapted from – APHL/CDC HIV Testing Algorithm: A status Report, April 2009
Methods

- Routine clinical specimens submitted for HIV testing
- Bio-Rad HIV-1/HIV-2 Plus O EIA (EIA)
- Bio-Rad Multispot HIV-1/HIV-2 (MS)
- Bio-Rad HIV-1 Western blot (WB)
- HIV-1 RNA PCR (in-house; Abbott Real Time HIV-1); HIV-2 WB (Focus) and HIV-2 RNA (in-house)
UW Algorithm

- If EIA negative: report “Not HIV infected”
- If EIA reactive
  - Forward for MS testing & repeat EIA in duplicate
    - Negative MS: forward for HIV-1 WB & initial report “presumptive not HIV infected”
    - Reactive MS: initial report “presumptive HIV infected” and forward for HIV-1 WB confirmation (or HIV-2 WB if appropriate)
- Confirmed HIV-1 WB: final report as “HIV-1 infection”
- Negative HIV-1 WB: final report as “No HIV-1 infection”
- Indeterminate WB and/or reactive MS forward for HIV-1 RNA (or further HIV-2 testing, if appropriate)
Results

- Between July 31, 2008 and Oct 8, 2009 a total of 13,943 HIV-1/-2 EI assays were performed
  - 242 specimens were EIA reactive of which
    - 203 (1.5%) were HIV-1 WB confirmed
      - 201 were MS HIV-1 + and 2 were MS HIV-2 +
    - 26 EIA+++/WB-/MS NEG
    - 7 EIA+++/WB-/MS NEG;
    - 6 EIA+++/WB IND/MS NEG
      - Of 13 EIA+++, 6 were available for HIV-1 RNA and 1/6 was RNA positive
Results (cont’d)

- 203 EIA+/HIV-1 WB+
  - 201/203 were MS HIV-1 POS
  - 2/203 were MS HIV-1 NEG/HIV-2 POS
    - WB #1 [gp160, p55, p31, p24] and WB #2 [gp160, p31, p24] both of which were initially signed-off as “HIV-1 infection confirmed” before the MS was done (old protocol); HIV-1 RNA negative
    - Confirmed with HIV-2 WB and HIV-2 RNA
Immunoblot

HIV-1
- ENV
  - gp160/gp120; gp41
- GAG
  - p55, p40, p24, p17
- POL
  - p66, p51, p31

HIV-2
- ENV
  - gp140/gp125; gp36/41
- GAG
  - p56, p26, p16
- POL
  - p68, p53, p34

WHO Wkly Epidem Rec 1990; 65(37): 281-88
Multispot assay performance for detection of HIV-1 antibodies

### HIV-1 Infection status†
(N=240)

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multispot HIV-1 +</td>
<td>201</td>
<td>0</td>
<td>100%</td>
<td>Positive PV</td>
</tr>
<tr>
<td>Multispot HIV-1 -</td>
<td>1</td>
<td>38</td>
<td>97.4%</td>
<td>Negative PV</td>
</tr>
</tbody>
</table>

†Determined by HIV-1 antibody or RNA and excludes two HIV-2 infected patients

3/29/2010

CDC/APHL 2010 Diagnostics Conference
Turn Around Time (TAT) in days to report a reactive EIA and WB or MS (N=242)
Summary

- Adjunctive MS testing allowed us to confirm reactive EIA results immediately and report “presumptive HIV infection,” pending further confirmation;
- Identified all false-positive EIA results;
- Shortened reporting time by a median of two days;
- Identified two (1%) of 203 EIA-reactive/HIV-1 WB “positive” results as cryptic HIV-2 infection
Conclusions

- These findings have important implications for the clinical management of HIV-infected persons, including timely clinical laboratory diagnosis of HIV infection, treatment of HIV-related conditions and use of appropriate antiretroviral therapy in HIV-2–infected patients.
Acknowledgements

Funding: UW CFAR (AI-27752)